Antiproliferative and apoptotic effects of angelicin in highly invasive prostate cancer cells
AbstractPurpose: To demonstrate the anti-proliferative activity of angelicin against human prostate cancer (PC- 3) cells and to evaluate its mechanism
Methods: MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay was used to assess the anticancer activity (growth inhibition) of angelicin in PC-3 cells. Fluorescence microscopy using Hoechst 33258 staining and inverted phase microscopy was employed to evaluate the effect of angelicin on nuclear morphology. Flow cytometry, using propidium iodide, was employed to study cell cycle-related effects of angelicin. Apoptosis induction by angelicin was examined by annexin V/PI assay.
Results: Angelicin induced potent growth inhibitory effects in human prostate cancer (PC-3) cells in a dose-dependent manner. Angelicin-treated cells exhibited chromatin condensation which implied an early apoptotic event. Inverted phase microscopy revealed that reduction of cell population occurred with increase in the angelicin dose. Flow cytometry results showed that angelicin induced cell cycle arrest in the sub-G1 phase. Angelicin induced both early and late apoptosis in PC-3 cells following a dose-dependent pattern.
Conclusion: Angelicin inhibits the growth of PC-3 human prostate cancer cells in vitro by inducing early and late apoptosis, cell cycle arrest and chromatin condensation.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.